Navigation Links
First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter
Date:5/19/2009

BURLINGTON, Mass. and ROTTERDAM, Netherlands, May 19 /PRNewswire/ -- InfraReDx, Inc. announced today the first use in patients of a novel coronary catheter that uses both light and sound to image coronary plaques. Working on a team led by Dr. Patrick Serruys, Dr. Martin van der Ent performed the procedures on May 11, 2009 in patients undergoing coronary angiography at the Thoraxcenter.

The combination catheter provides the benefits of both IVUS and NIRS imaging in a single study of the artery. IVUS is a well-established technique that is in common use to quantify the degree of narrowing produced by a plaque, the size of the artery and the adequacy of stent expansion. NIRS is a novel technique recently cleared by the FDA for the identification of lipid core plaques, the structures suspected to cause most heart attacks and complicate stenting procedures.

Prof. Serruys stated that, "The composition of atherosclerotic plaques is important in assessing the likelihood that they will cause cardiovascular events. This novel device provides composition on top of anatomy and will play a pivotal role in interventional cardiology, first in clinical trials and further on in treatment planning in individual patients."

The Biomedical Engineering Department of the Thoraxcenter, led by Prof. Dr. Ton van der Steen, provided expertise essential to the addition of IVUS to the NIRS system.

"In order to determine both composition and structure of an atherosclerotic plaque, a combination catheter is necessary. I am truly excited that InfraReDx teamed up with the Thoraxcenter in this development, both from a technical and a clinical perspective," says Prof. van der Steen.

James E. Muller, M.D., cardiologist, co-founder and CEO of InfraReDx stated that, "The InfraReDx team is proud to have developed the first combined optical and acoustic catheter for use in the coronary arteries of patients. The addition of IVUS to our FDA cleared LipiScan(TM) catheter provides a novel tool that we believe will assist physicians with the complex decisions they face in the management of patients with coronary artery disease."

Live patient case to be broadcast at EuroPCR Conference this week

On Wednesday, May 20, Dr. van der Ent will be performing a live case with the combined catheter from the Thoraxcenter for the EuroPCR Conference taking place this week in Barcelona, Spain from May 19 - 22, 2009.

About The LipiScan(TM) Coronary Imaging System

The LipiScan(TM) Coronary Imaging System is a catheter-based device that uses laser light to detect how much fat and other substances are contained in a plaque. The identification of the chemical composition of coronary plaques is expected to be of initial value to cardiologists in efforts to improve the safety of stenting procedures, and selection of intensity of lipid altering therapy. The longer-term goal of identification and management of lipid core plaques is to prevent the occurrence of acute coronary syndromes. The device is also expected to be of value to the pharmaceutical industry as a means to assess the effect of novel anti-atherosclerotic agents on lipid core plaque burden.

About InfraReDx, Inc.

InfraReDx, Inc. is a science-based medical device company with expertise in technologies useful for characterization of coronary plaques. The company first developed a system utilizing near-infrared spectroscopic (NIRS) technology to identify plaque composition. It has now developed IVUS technology to provide complementary information about the structure of plaques. The company, located in Burlington, Mass., was founded in 1998 to meet the unmet medical need for detection and identification of lipid core containing plaques of interest in the coronary arteries. For more information, visit the InfraReDx website at www.infraredx.com.

    Thoraxcenter Contact:

    David Drexhage, Press Officer
    Communications Department
    Erasmus MC
    P.O. Box 2040
    3000 CA Rotterdam, NL

    Tel +31 10 703 55 25
    d.drexhage@erasmusmc.nl

    InfraReDx Company Contacts:

    Technology Contact:

    Mark A. Wilder, Vice President Business and Advanced Development
    InfraReDx, Inc.
    (781) 221-0053
    mwilder@infraredx.com

    Investor Contact:

    Jeff Mazur, Controller
    InfraReDx, Inc.
    (781) 221-0053
    jmazur@infraredx.com


'/>"/>
SOURCE InfraReDx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments
2. Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices)
3. Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results
4. China Biologic Products Announces Strong First Quarter 2009 Results
5. The Institut Pasteur and Merieux Alliance Take First Step Towards a Long-Term Research Partnership in the Field of Infectious Diseases
6. Rodobo International, Inc. Reports Q2 and First Half of 2009
7. China Biologic Products Announces 2009 First Quarter Results Conference Call
8. PharmAthene Reports First Quarter 2009 Financial and Operational Results
9. Tiens Biotech Group (USA) Reports First Quarter Results
10. Spectral announces first quarter 2009 results
11. Oncothyreon reports first quarter 2009 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
Breaking Biology News(10 mins):